Aquestive Therapeutics (AQST) provided an update on recent business developments and outlined key objectives for 2025. On track to submit Anaphylm Sublingual Film NDA in Q1 2025; Actively recruiting subjects in the Anaphylm pediatric clinical trial; Successfully completed AQST-108 Topical Gel pre-IND meeting and on track to begin Phase 2a clinical trial in alopecia areata in Q2 2025; Unaudited cash and cash equivalents of approximately $70 million as of December 31, 2024.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener